Benzimidazole derivatives are frequently used to treat trichinellosis. However, drug resistance, 
adverse effects, and low bioavailability restrict their therapeutic use in treating Trichinella infec
tions. The need for a novel, secure and efficient anti-trichinellosis treatment is therefore impera
tive. Artemisia judaica showed strong anthelmintic and antiprotozoal properties. The study eval
uated the effectiveness of A. judaica extract compared with Albendazole alone or loaded on sil
ver nanoparticles in trichinellosis infected mice. Mice were classified into 7 groups: GI: negative 
control, GII: positive control, GIII: infected treated with silver nanoparticles, GIV: infected 
treated with Artemisia judaica extract, GV: infected treated with albendazole, GVI: infected 
treated with Artemisia judaica extract loaded on silver nanoparticles and GVII: infected treated 
with albendazole loaded on silver nanoparticles. They were equally divided into two subgroups 
based on euthanasia time at 7th & 35th days post infection. Parasitological, immun- ological, and 
histopathological analyses were carried out to assess the efficacy of the treatment. Artemisia ju
daica extract loaded on silver nanoparticles treated mice induced a significant reduction in mean 
number of T. spiralis adults and larvae in infected mice, restored normal intestinal structure, and 
reduced  pathogenic impact of infection by a significant decrease in GPx and SOD activities and 
immunomodulation of proinflammatory (TNF-α) and anti-inflammatory (IL-6, IL-10) cytokines. 
They may be useful as prospective trichinellosis treatment.